Week in Review: Chindex Taken Private by Fosun and TPG for $434 Million

Chindex accepted a buy-out offer of $24 per share from Fosun Pharma and TPG, the US private equity investor, which values the company at $434 million; GlaxoSmithKline paid $7.1 billion for Novartis’ money-losing vaccine business that includes China facilities; Domain Elite invested $6.5 million in Israeli device maker SMART Medical to help SMART bring its products to China; Fosun Pharma may buy Australia's Healthscope, a $5 billion hospital and pathology company; Beckman Coulter acquired Xitogen Technologies of Suzhou, a maker of flow cytometry equipment; Fosun Pharma acquired China rights to PaMZ, a novel TB drug regimen developed by the TB Alliance; Yichang Chang Jiang Pharma will supply Biodel of the US with research supplies of the API for a fast-acting insulin; Eddingpharm in-licensed China distribution rights to two allergy products made by Danish pharma ALK; and Sinovac landed a $9.6 million government grant to build a production facility for its hand foot and mouth disease vaccine. More details…. Stock Symbols: (NSDQ: CHDX) (SHA: 000196; HK: 2196) (NYSE: GSK) (NYSE: NVS) (NSDQ: BIOD) (CO: ALK-B) (NSDQ: SVA) Share this with colleagues: // //